P/E ratio for Calithera Biosciences (CALA)
P/E ratio as of April 2024 (TTM): -0.0037
According to Calithera Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.00368324. At the end of 2021 the company had a P/E ratio of -0.0215.
P/E ratio history for Calithera Biosciences from 2014 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -0.0215 | -88.5% |
| 2020 | -0.1874 | 28.66% |
| 2019 | -0.1457 | 8.25% |
| 2018 | -0.1346 | -72.6% |
| 2017 | -0.4912 | 492.43% |
| 2016 | -0.0829 | -60.82% |
| 2015 | -0.2116 | -66.86% |
| 2014 | -0.6384 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | 14.9 | -404,659.57% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
 Aeterna Zentaris AEZS | -0.4198 | 11,297.17% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.